
Phase 1/2 Trial Investigating ATR-04 for EGFRi-Related Rashes in Lung Cancer
The phase 1/2 ATR04-484 clinical trial is examining ATR-04 therapy for the treatment of EGFR inhibitor-associated rashes in patients with non-small cell lung cancer, colorectal cancer and others, according to a news release from Azitra, Inc., a …